Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96AT9

UPID:
RPE_HUMAN

ALTERNATIVE NAMES:
Ribulose-5-phosphate-3-epimerase

ALTERNATIVE UPACC:
Q96AT9; A8K4S0; B4E016; C9JPQ7; O43767; Q53TV9; Q8N215; Q96N34; Q9BSB5

BACKGROUND:
The enzyme Ribulose-phosphate 3-epimerase, alternatively known as Ribulose-5-phosphate-3-epimerase, is integral to the pentose phosphate pathway, facilitating the conversion of D-ribulose 5-phosphate into D-xylulose 5-phosphate. This reaction is vital for the biosynthesis of nucleotides, underscoring the enzyme's significance in cellular metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Ribulose-phosphate 3-epimerase offers a promising avenue for the development of novel therapeutic approaches. Given its critical role in the metabolic pathways that support cell growth and maintenance, targeting this enzyme could provide new strategies for managing conditions associated with abnormal cellular proliferation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.